The Value of Admission Serum IL-8 Monitoring and the Correlation with IL-8 (-251A/T) Polymorphism in Critically Ill Patients

Ayman Abd Al-Maksoud Yousef, Ghada Abdulmomen Suliman, and Maaly Mohamed Mabrouk

Faculty of Medicine, Tanta University, Tanta, Egypt

Correspondence should be addressed to Ayman Abd Al-Maksoud Yousef; ayman.yousef@rocketmail.com

Received 4 September 2013; Accepted 12 October 2013; Published 6 March 2014

1. Introduction

Sepsis constitutes a complex syndrome in critically ill patients, which usually correlates with bad prognosis; the outcome of sepsis is mostly determined by major interaction between the host, the invading microorganism, and the surrounding environment. Wide variability exists in the susceptibility to and outcome from sepsis even within similar intensive care unit populations. Some of this variability in the host may be due to genetic variation in genes coding for components of the innate immune response.

Genetic association studies suggest a major genetic influence on outcome of sepsis. Dysregulation of innate immunity, especially those genes involved in inflammatory pathway, is expected to be the determinant for manifestation of sepsis [1, 2]. Evaluation of the association between the genetic polymorphism in septic patients provides a new tool to predict prognosis [3]. Interlukine-8 (IL-8) is a proinflammatory cytokine, has a potential role in regulating the innate immune response to bacterial infection, and has become crucial in the management, early prediction, monitoring and success of antimicrobial therapy in critically ill patients [4]. IL-8 belongs to CXC chemokine family, which is the major neutrophil chemo-attractant and activator. Genetic polymorphism in IL-8 at position -251 had been previously studied in various pathological conditions; furthermore, this polymorphism was associated with diseases that include respiratory syncytial virus [5]. So, the present study is conducted to determine the value of serum IL-8 monitoring and the role of IL-8 (-251A/T) polymorphism and its correlation with survival in critically ill patients.
2. Materials and Methods

After the study was approved by an Investigational Review Board, an informed consent was obtained from patients participating in the study or their relatives. This study was conducted in the ICU of Emergency Hospital of Tanta University, Tanta, Egypt. It is a 25-bed medical/surgical ICU. A total of one hundred eighty adult intensive care patients (97 men and 83 women) were included in the study. Ninety patients developed septic complication during ICU stay (sepsis group). Ninety patients were critically ill without evidence of infectious organism (SIRS group). Patients received anti-inflammatory drugs or corticosteroids before admission, patients with immunosuppressive illness, patients with chronic organ failure; patients received massive blood transfusion and patients with radiation therapy or previous organ transplantation were excluded from the study. At admission, the patient’s age, sex, height, and weight were recorded, in addition to clinical status; sequential organ failure assessment (SOFA) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin, and CRP); and arterial blood gas analysis were measured. Routine cultures of blood, urine and suspected sites were obtained to determine the presence of infection. We attempted to maintain the patient hemoglobin level at 10–12 g/dL and central venous pressure at 8–12 cm H₂O. If needed, blood products, intravenous fluid replacement, and inotropic and/or vasopressor agents were administered. Each day the attending physician in the ICU evaluated all the study patients for sepsis, severe sepsis, or septic shock.

The signs of sepsis were body temperature <36°C or >38°C, tachycardia (>90 beats/min), ventilatory frequency >20 breath/min or PCO₂ <32 mmHg (unless the patient was mechanically ventilated), a white cell count ≥12 × 10⁹ litre⁻¹ or < 4 × 10⁹ litre⁻¹, or > 10% immature neutrophils, in addition to the presence of infection [6]. Severe sepsis was defined as sepsis with evidence of organ dysfunction and hypoperfusion, acute alteration of mental status, elevated plasma lactate, unexplained metabolic acidosis (arterial pH < 7.3), hypoxaemia, prolonged prothrombin time or decrease in platelet count > 50% or ≤ 100 × 10⁹ litre⁻¹, oliguria, and hypotension defined as systolic arterial pressure < 90 mmHg or a decrease of > 40 mmHg. Septic shock was defined as hypotension (< 90/60 mmHg) in addition to sepsis syndrome persisting despite adequate fluid resuscitation and requiring inotropic support [6]. The SOFA score is composed of scores from six organ systems (respiratory R, cardiovascular C, hepatic H, coagulation Co, renal Re, and neurological N) graded from 0 to 4 according to the degree of dysfunction/failure. The aggregate score (total maximum SOFA score TMS) is calculated summing the worst scores for each of the organ systems (TMS_org) during the ICU stay [7].

2.1. Estimation of Serum IL-8. Serum level of IL-8 was determined by quantitative sandwich enzyme immunoassay (R&D Systems, Inc., Minneapolis, MN, USA) according to the manufacturer’s instructions. The intensity of the colour was measured at 490 nm for IL-8.

2.2. Estimation of IL-8 Gene Polymorphism. About 4 mL blood is withdrawn in EDTA-tubes and the genomic DNA was extracted using QIA amp DNA minikit from QIA-GEN according to the manufacture instruction. Concentration of the extracted DNA was then measured by UV spectrophotometry (Pharmacia, Biotech, UK) at 260 and 280 nm and run on agarose gel electrophoresis 2% for detection of purity. Molecular detection of the (-251A/T) polymorphism in the IL-8 gene was achieved by restriction fragment length polymorphism typing. This included a combination of PCR amplification (Gene Amp PCR system 9700 from applied Biosystem) and digestion with restriction endonuclease Muni II followed by gel electrophoretic analysis. Primer sequences for PCR were designed by Applied Biosystem. The primers used were forward: 5'-ATCTTGTTCACCATGCCACTCT-3' and reverse: 5'-TAAAATACTGAGGCACATTTGG-3'. PCR was carried out in a volume of 50 µL containing 5 µL (250 ng) of genomic DNA, 25 µL PCR Master Mix (containing 50 units/µL Taq DNA polymerase, supplied in a proprietary reaction buffer, pH 8.5, 400 µM each: dATP, dGTP, dCTP, dTTP and 3 mM MgCl₂), 5.0 µL of each primer (10 µM) and finally 10 µL Nuclease-Free Water (Applied System, Foster city, CA, USA). The PCR conditions consisted of an initial denaturation step at 94°C, followed by 35 cycles of 94°C for 50 sec, 61°C for 1 min, 72°C for 55 seconds, and lastly a final elongation step at 72°C for 5 min were carried out. The amplification products were digested with Mun I restriction enzyme (Fermentas, Ottawa, ON, Canada) for 4 hours at 37°C, subjected to electrophoresis on 2% agarose gels stained with ethidium bromide. The generated PCR product of 121 bp was cleaved by restriction enzyme into fragments of 82 bp and 39 bp only if the A allele was present.

2.3. Statistical Analysis. Parametric data were analyzed using Student’s t-test, while nonparametric data were analyzed using Mann-Whitney U and χ²-tests. Data were presented as mean and standard deviation. A P value of < 0.05 was considered significant. We calculated that we need 87 patients per group to have an 80% chance of detecting a 25% change in serum IL-8 at a 5% significance level, with a 2-sided significance level (nQuery Advisor, Version 5.0), so we included 90 patients per group.

3. Results

A total of 180 patients (97 men and 83 women) were included in the study. Ninety patients developed septic complication during ICU stay (sepsis group) in this group; eighteen patients developed septic shock and twenty eight patients developed severe sepsis. Ninety patients were critically ill without evidence of infectious organism (SIRS group). Forty-four patients died, fourteen of them were in septic shock and twenty were suffering from severe sepsis, while ten patients...
died in SIRS. There was no significant difference between the groups, except for SOFA score at ICU admission, the duration of the stay the ICU, and mortality rate which were higher in septic patients (Table 1).

The admission mean value of serum IL-8 is statistically significantly elevated in sepsis group which was 419.22 pg/mL with a range of (190–850 pg/mL) when compared to mean value in SIRS group which was 181.44 pg/mL with a range of (110–310 pg/mL) \( (P < 0.001) \) (Table 2).

The mortality rate is significantly higher in sepsis group, 34 patients died, while 56 patients survived. In SIRS group, 10 patients died, while 80 patients survived \( (P < 0.001) \) (Table 3).

In sepsis group, the mean value of serum IL-8 in survived patients was 297.679 ± 73.855 pg/mL which is significantly lower in comparison to the mean value in non-survived patients which is 619.412 ± 117.097 pg/mL \( (P < 0.001) \). In SIRS patients, the mean value of serum IL-8 in survived patients was 175.75 ± 36.380 pg/mL which is significantly lower in comparison to mean value in non-survived patients which is 227 ± 18.738 pg/mL \( (P < 0.001) \) (Table 4).

The incidence of gene mutation IL-8 (-251A/T) allele is similar in both groups. In sepsis group, 15 patients showed IL-8 (-251A/T) genetic polymorphism compared to 13 patients in SIRS group \( (P = 0.681) \) (Table 5).

In sepsis group, the mean value of serum IL-8 in patients with IL-8 (-251A/T) mutant allele was 694.333 ± 64.278 pg/mL which is significantly higher in comparison to mean value in patients with wild gene which is 364.2 ± 143.421 pg/mL \( (P < 0.001) \). In SIRS patients, the mean value of IL-8 in patients with IL-8 (-251A/T) mutant allele was 227.308 ± 43.235 pg/mL which was significantly higher in comparison to mean value in patients with wild gene which was 173.701 ± 31.762 pg/mL \( (P < 0.001) \) (Table 6).

A positive correlation of survival and IL-8 (-251A/T) mutant allele was detected in sepsis and SIRS patients respectively \( (P < 0.001) \) (Table 7).

The serum IL-8 distinguished sepsis from SIRS at a cut-off value of 230 pg/mL and demonstrated a sensitivity of 88.9%, specificity of 95%, and accuracy level of 0.957 with a positive predictive value of 96.4 and negative predictive value of 85.1 (Figure 1).

The serum IL-8 in distinguished survived from non-survived patients in sepsis from SIRS patients at a cut-off value of 420 pg/mL and demonstrated a sensitivity of 77.3%, specificity of 96.2%, and accuracy level of 0.891 with a positive predictive value of 89.5 and negative predictive value of 91.5 (Figure 3).

### 4. Discussion

This novel study to our knowledge is the first to evaluate serum IL-8 and its genetic 251 polymorphism and the correlation of survival in critically ill septic and SIRS patients. Our study demonstrated that the admission mean value of serum IL-8 is significantly elevated in sepsis group; the mean value of serum IL-8 in non-survived patients is significantly higher than survived patients. The mean value of serum IL-8 in patients with IL-8 (-251A/T) mutant allele is significantly
had been attributed to a number of factors. Evidence is 
may progress to death. This variability of patients' outcome 
multiple organ system failure, refractory hypotension, and 
will recover, while small portion may develop severe sepsis, 
populations. Given the same medications, most patients 
astreatmentandprognosis. 
is likely to have an impact on clinical manifestations as well 
population make it clear that an individual's genetic makeup 
the degree of genetic variation that exists in the human 
do they have identical prognosis or response to treatment. 
higher than patients with wild allele. A positive correlation 
of survival and IL-8 (-251A/T) mutant allele was detected 
in sepsis and SIRS patients, respectively. The serum IL-8 
distinguished wild from patients with IL-8 (-251A/T) mutant 
elicently ill patients. 
It has been long realized that not all individuals with a 
spicific insult present with the same clinical pictures, nor 
do they have identical prognosis or response to treatment. 
The sequencing of the human genome and recognition of 
the degree of genetic variation that exists in the human 
population make it clear that an individual's genetic makeup 
is likely to have an impact on clinical manifestations as well 
as treatment and prognosis. 
The response to infection is variable among different 
populations. Given the same medications, most patients 
will recover, while small portion may develop severe sepsis, 
multiple organ system failure, refractory hypotension, and 
may progress to death. This variability of patients’ outcome 
had been attributed to a number of factors. Evidence is 
accumulating to support the theory that the genetic makeup 
of the host plays an important role in susceptibility to and 
development of sepsis, as well as its severity and prognosis. 
The genetic predisposition to the development of sepsis and 
to poor outcome from sepsis strongly exists [8]. 
Sequencing of the human genome had revealed that 
many genes are polymorphic, including some of the genes 
that have been implicated in the development of sepsis. The 
polymorphic gene is the gene in which comparison of the 
DNA sequence in multiple individuals shows differences at 
a frequency of 1%. These sites within the genes are called 
polymorphic sites. Some of these variations had been shown 
to influence the level and the activity of the resulting protein, 
thereby affecting cell function. The genes most likely to play 
a role in the susceptibility to and outcome from sepsis are 
mostly polymorphic genes that encode for protein products 
involved in the pathogenesis of sepsis [9]. 
The central event in the pathophysiology of sepsis is the 
release of proinflammatory cytokines in response to an inciting 
stimulus, such as a bacterial infection. Normally, these 
cytokines activate a variety of cellular and humoral systems 
that are responsible for eliminating this stimulus. However, 
an exaggerated inflammatory response leads to excessive pro-
duction of these mediators resulting in an imbalance between 
the proinflammatory and the anti-inflammatory cytokines 
and consequently leads to the clinical manifestations of severe 
sepsis and multiple organ failure syndromes [10]. 
A number of the components involved in the body's 
response to bacterial infection and sepsis are encoded by 
polymorphic genes, including proteins involved with intra-
cellular response to bacterial products such as interleukins 
(ILs). IL-8 is one of the pro-inflammatory cytokine; it belongs 
to the chemokine gene family of cytokines. It is produced by 
mononuclear phagocytes, endothelial cells, polymorphonu-
clear leucocytes, and a variety of mesothelial cell types in 
response to various stimuli. Its primary function is to activate 
and attract neutrophils to sites of inflammation [11]. 
Wong et al. [12] demonstrated increased IL-8 mRNA 
and protein in nonsurvivors of septic shock. Others demon-
strated that initial IL-8 levels predict a high likelihood of 
survival in children and septic shock [13]. IL-8 is considered 
as a secondary pro-inflammatory cytokine with important 
chemotactic properties in systemic inflammation [14]. 
Miller et al. [15] demonstrated that IL-8 had been 
associated with inflammatory process in lung dysfunction 
in patients suffering from multiple organ dysfunction syn-
dromes. 
Biron et al. [16] demonstrated that serum level of IL-8 
had been correlated with the course of sepsis in patients with 
lactacidemia. In addition, it had been reported that plasma 
IL-8 concentration was elevated in patients with sepsis and 
higher serum concentration correlate with mortality [17, 18]. 
Many studies have been indicated that polymorphisms 
in some of the genes are involved in the pathogenesis of 
sepsis. Genetic polymorphism in IL-8 at position-251 had 
been previously studied in various pathological conditions 
and this mutation had shown to be associated with increased 
IL-8 production; furthermore, this polymorphism was asso-
ciated with diseases that include respiratory syncytial virus

| Table 4: Concentration of serum IL-8 in survived and nonsurvived patients in the studied groups. |
|--------------------------------------------------------|
| Groups       | Survival (Mean ± SD) | Nonsurvival (Mean ± SD) | t-test | P value |
|--------------|----------------------|-------------------------|--------|---------|
| IL-8 Sepsis  | 297.679 ± 73.855     | 619.412 ± 117.097       | −16.003 | <0.001* |
| SIRS         | 175.750 ± 36.380     | 227.000 ± 18.738        | −4.367  | <0.001* |

*Statistically significant.

| Table 5: Incidence of gene mutation in the studied groups. |
|-----------------------------------------------------------|
| Gene mutation       | Sepsis | Groups | SIRS | Total |
|--------------------|--------|--------|------|-------|
| Wild               |        |        |      |       |
| N                  | 75     | 77     | 152  |       |
| %                  | 83.33  | 85.56  | 84.44|       |
| Mutant             |        |        |      |       |
| N                  | 15     | 13     | 28   |       |
| %                  | 16.67  | 14.44  | 15.56|       |
| Total              |        |        |      |       |
| N                  | 90     | 90     | 180  |       |
| %                  | 100.00 | 100.00 | 100.00|       |
| Chi-square         |        |        |      |       |
| \(\chi^2\)         |        | 0.169  |      |       |
| \(P\) value        |        | 0.681  |      |       |

| Table 6: Concentration of serum IL-8 in patients with IL-8 (-251A/T) polymorphism in the studied groups. |
|--------------------------------------------------------|
| Groups       | Wild (Mean ± SD) | Mutant (Mean ± SD) | t-test | P value |
|--------------|------------------|-------------------|--------|---------|
| IL-8 Sepsis  | 364.200 ± 143.421| 694.333 ± 64.278  | −8.711 | <0.001* |
| SIRS         | 173.701 ± 31.762 | 227.308 ± 43.235 | −5.327 | <0.001* |

*Statistically significant.
Table 7: Correlation of survival and IL-8 (-251A/T) polymorphism in the studied groups.

| Gene mutation | Survival | Nonsurvival | Total | Chi-square | P value |
|---------------|----------|-------------|-------|------------|---------|
|               | N         | %           | N     | %          |         |
| Sepsis        |           |             |       |            |         |
| Normal        | 56        | 62.22       | 19    | 21.11      | 75      | 83.33   |
| Poly          | 0         | 0.00        | 15    | 16.67      | 15      | 16.67   |
| Total         | 56        | 62.22       | 34    | 37.78      | 90      | 100.00  |
| SIRS          |           |             |       |            |         |
| Normal        | 73        | 81.11       | 4     | 4.44       | 77      | 85.56   |
| Poly          | 7         | 7.78        | 6     | 6.67       | 13      | 14.44   |
| Total         | 80        | 88.89       | 10    | 11.11      | 90      | 100.00  |

*Statistically significant.

---

Figure 1: ROC curve of IL-8 in sepsis and SIRS patients.

ROC curve of IL-8 in sepsis and SIRS patients

| Cutoff | Sens. | Spec. | PPV  | NPV  | Accuracy |
|--------|-------|-------|------|------|----------|
| >230   | 88.9  | 95.0  | 96.4 | 85.1 | 0.957    |

Figure 2: ROC curve of IL-8 in survived and nonsurvived patients.

ROC curve of IL-8 in survived and nonsurvived patients

| Cutoff | Sens. | Spec. | PPV  | NPV  | Accuracy |
|--------|-------|-------|------|------|----------|
| >420   | 77.3  | 96.2  | 89.5 | 91.1 | 0.891    |
infection [5]. Baier et al. [19] studied the possibility of genetic association with septic complications and concluded that single nucleotide polymorphism of IL-6, IL-10, and C14 polymorphism may alter the risk of blood stream infection in ventilated very low birth weight infant.

Arnalich et al. [20] studied the polymorphism of IL-1 receptor agonist (IL-1Ra) gene on the outcome of severe sepsis and its effect on total production of interlukin-1 receptor antagonist protein and concluded that patients with polymorphism produced significantly lower level of IL-Ra which may contribute to higher mortality rate found in severe sepsis.

Schaaf et al. [21] studied the effect of interlukin-10, tumor necrosis factor alpha and lymphotoxin-alpha polymorphism regarding the development of septic shock in pneumococcal infection and concluded that patients with genetic predisposition for polymorphism may have higher risk of severe pneumococcal infection leading to septic shock. Wurfel et al. [22] studied the effect of single-nucleotide polymorphism (SNPs) affecting Toll-like receptor-mediated responses in healthy volunteer and found that genetic variation is associated with increased susceptibility to organ dysfunction, death, and gram-positive infection in sepsis. A strong association had been confirmed between TNF-α polymorphisms and the clinical presentation or outcome in patients with sepsis and septic shock [23, 24].

5. Conclusion

The admission mean value of serum IL-8 is significantly elevated in septic patients. Significant elevation in serum IL-8 in nonsurvived patients and patients with IL-8 (-251A/T) mutant alleles. A positive correlation of survival and IL-8 (-251A/T) mutant allele patients was detected. The serum IL-8 distinguished wild from patients with IL-8 (-251A/T) mutant allele critically ill patients.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

[1] S. Yende and J. A. Kellum, “Understanding genetics of sepsis: will new technology help?” Critical Care, vol. 13, no. 3, article 141, 2009.
[2] M. K. Dahmer, A. Randolph, S. Vitali, and M. W. Quasney, “Genetic polymorphisms in sepsis,” Pediatric Critical Care Medicine, vol. 6, no. 3, pp. S61–S73, 2005.
[3] A. M. Sutherland and J. A. Russell, “Issues with polymorphism analysis in sepsis,” Clinical Infectious Diseases, vol. 41, supplement 7, pp. S396–S402, 2005.
[4] J. Winning, R. A. Claus, K. Huse, and M. Bauer, “Molecular biology on the ICU from understanding to treating sepsis,” Minerva Anestesiologica, vol. 72, no. 5, pp. 255–267, 2006.
[5] J. Hull, A. Thomson, and D. Kwiatkowski, “Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families,” Thorax, vol. 55, no. 12, pp. 1023–1027, 2000.
[6] American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference, “Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis,” Critical Care Medicine, vol. 20, pp. 864–874, 1992.
[7] U. Janssens, R. Dujardin, J. Graf et al., “Value of SOFA (sequential organ failure assessment) score and total maximum SOFA score in 812 patients with acute cardiovascular disorders,” Critical Care, vol. 5, supplement 1, p. 225, 2001.
[8] T. I. A. Sorensen, G. G. Nielsen, P. K. Andersen, and T. W. Teasdale, “Genetic and environmental influences on premature
death in adult adoptees," The New England Journal of Medicine, vol. 318, no. 12, pp. 727–732, 1988.

[9] K. R. Walley, N. W. Lukacs, T. J. Standiford, R. M. Strieter, and S. L. Kunkel, "Balance of inflammatory cytokines related to severity and mortality of murine sepsis," Infection and Immunity, vol. 64, no. 11, pp. 4733–4738, 1996.

[10] T. S. Blackwell and J. W. Christman, "Sepsis and cytokines: current status," British Journal of Anaesthesia, vol. 77, no. 1, pp. 110–117, 1996.

[11] Y. Hirao, T. Kanda, Y. Aso, M. Mitsuhashi, and I. Kobayashi, "Interleukin-8—an early marker for bacterial infection," Laboratory Medicine, vol. 31, no. 1, pp. 39–44, 2000.

[12] H. R. Wong, T. P. Shanley, B. Sakthivel et al., "Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome," Physiological Genomics, vol. 30, no. 2, pp. 146–155, 2007.

[13] H. R. Wong, N. Cvijanovich, D. S. Wheeler et al., "Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock," The American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 3, pp. 276–282, 2008.

[14] J. S. Solomkin, R. C. Bass, H. S. Bjornson, C. J. Tindal, and G. F. Babcock, "Alterations of neutrophil responses to tumor necrosis factor alpha and interleukin-8 following human endotoxemia," Infection and Immunity, vol. 62, no. 3, pp. 943–947, 1994.

[15] E. J. Miller, A. B. Cohen, and M. A. Matthay, "Increased interleukin-8 concentrations in the pulmonary edema fluid of patients with acute respiratory distress syndrome from sepsis," Critical Care Medicine, vol. 24, no. 9, pp. 1448–1454, 1996.

[16] C. Biron, C. Bengler, J. C. Gris, and J. F. Schved, "Acquired isolated factor VII deficiency during sepsis," Haemostasis, vol. 27, no. 2, pp. 51–56, 1997.

[17] C. Marty, B. Misset, F. Tamion, C. Fitting, J. Carlet, and J.-M. Cavaillon, "Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and nonseptic origin," Critical Care Medicine, vol. 22, no. 4, pp. 673–679, 1994.

[18] C. E. Hack, M. Hart, R. J. M. S. van Schijndel et al., "Interleukin-8 in sepsis: relation to shock and inflammatory mediators," Infection and Immunity, vol. 60, no. 7, pp. 2835–2842, 1992.

[19] R. J. Baier, J. Loggins, and K. Yanamandra, "IL-10, IL-6 and CD14 polymorphisms and sepsis outcome in ventilated very low birth weight infants," BMC Medicine, vol. 4, article 10, 2006.

[20] F. Arnalich, D. Lopez-Maderuelo, R. Codoco et al., "Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis," Clinical and Experimental Immunology, vol. 127, no. 2, pp. 331–336, 2002.

[21] B. M. Schaaf, F. Boehmke, H. Esnaashari et al., "Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism," The American Journal of Respiratory and Critical Care Medicine, vol. 168, no. 4, pp. 476–480, 2003.

[22] M. M. Wurfel, A. C. Gordon, T. D. Holden et al., "Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis," The American Journal of Respiratory and Critical Care Medicine, vol. 178, no. 7, pp. 710–720, 2008.

[23] O. Appoloni, E. Dupont, M. Vanderruys, M. Andriens, J. Duchateau, and J.-L. Vincent, "Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock," The American Journal of Medicine, vol. 110, no. 6, pp. 486–488, 2001.

[24] M. Majetschak, U. Obertacke, F. U. Schade et al., "Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients," Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 6, pp. 1205–1211, 2002.